Design, synthesis and evaluation of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes

被引：0
|
作者：
Das, Saibal Kumar [1 ]
Abbineni, Chandrasekhar [1 ]
Rao, Krovvidi Venkata Lakshmi Narasimha [1 ]
Iqbal, Javed [1 ]
Babu, Ravi Krishna [1 ]
Chakrabarti, Ranjan [1 ]
机构：
[1] Dr Reddys Labs Ltd, Metab Disorders Grp, Discovery Res, Hyderabad 500049, Andhra Pradesh, India
来源：
LETTERS IN DRUG DESIGN & DISCOVERY | 2007年 / 4卷 / 01期
关键词：
PPAR; diabetes; synthesis; ethyl 3-(4-aminophenyl)-2-ethoxypropionate; dyslipidemia and plasma glucose;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The design, synthesis and evaluation of several dual PPAR alpha/gamma agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPAR alpha/gamma agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.
引用
收藏
页码：27 / 32
页数：6
相关论文
共 50 条
  • [1] Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-γ/δ dual agonists
    Gim, Hyo Jin
    Cheon, Ye-Jin
    Ryu, Jae-Ha
    Jeon, Raok
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (10) : 3057 - 3061
  • [2] Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists
    Eeda, Venkateswararao
    Wu, Dan
    Lim, Hui-Ying
    Wang, Weidong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (22)
  • [3] Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor α/δ dual agonists
    Kasuga, J
    Makishima, M
    Hashimoto, Y
    Miyachi, H
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (03) : 554 - 558
  • [4] Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists
    Kasuga, Jun-ichi
    Nakagome, Izumi
    Aoyama, Atsushi
    Sako, Kumiko
    Ishizawa, Michiyasu
    Ogura, Michitaka
    Makishima, Makoto
    Hirono, Shuichi
    Hashimoto, Yuichi
    Miyachi, Hiroyuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (15) : 5177 - 5190
  • [5] Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes
    Blaschke, F
    Takata, Y
    Caglayan, E
    Law, RE
    Hsueh, WA
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) : 28 - 40
  • [6] Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
    Jean-Charles Fruchart
    Cardiovascular Diabetology, 12
  • [7] Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists
    Yamazaki, Yukiyoshi
    Abe, Kazutoyo
    Torna, Tsutornu
    Nishikawa, Masahiro
    Ozawa, Hidefurni
    Okuda, Ayurnu
    Araki, Takaaki
    Odaa, Soichi
    Inoue, Keisuke
    Shibuya, Kimiyuki
    Staels, Bart
    Fruchart, Jean-Charles
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (16) : 4689 - 4693
  • [8] Thiazolidinediones in type 2 diabetes.: Role of peroxisome proliferator-activated receptor γ (PPARγ)
    Dubois, M
    Vantyghem, MC
    Schoonjans, K
    Pattou, F
    ANNALES D ENDOCRINOLOGIE, 2002, 63 (06) : 511 - 523
  • [9] Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
    Jay, Mollie A.
    Ren, Jun
    CURRENT DIABETES REVIEWS, 2007, 3 (01) : 33 - 39
  • [10] Selective peroxisome proliferator-activated receptora modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
    Fruchart, Jean-Charles
    CARDIOVASCULAR DIABETOLOGY, 2013, 12
12345